Trials / Unknown
UnknownNCT03741010
Belviq Tablet® Post Marketing Surveillance Protocol
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- —
Summary
Post-marketing surveillance of Lorcaserin
Detailed description
Lorcaserin(Belviq) is a selective 5-hydroxytryptamine receptor agonist, witch is used long term for weight loss in those who are obese. Lorcaserin was approved in 2015 the Republic of Korea for weigh loss in those who are obese. A post-marketing surveillance was conducted following the approval to obtain data on the safety and efficacy of lorcaserin for weigh loss in real-world practice.
Conditions
Timeline
- Start date
- 2015-02-02
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2018-11-14
- Last updated
- 2018-11-26
Source: ClinicalTrials.gov record NCT03741010. Inclusion in this directory is not an endorsement.